Immunology Sponsored by Beckman Coulter
Researchers develop mouse model of COVID-19 infection
Researchers have generated a strain of SARS-CoV-2 that can infect mice and used it to produce a new mouse model of infection to help facilitate testing of COVID-19 vaccine candidates and therapies. The research article was published in Science on July 30.  Discuss
Animal study turns in positive results for Moderna-NIH COVID-19 vaccine
Moderna's COVID-19 vaccine candidate, messenger RNA (mRNA)-1273, has been shown to induce immune responses and control upper and lower respiratory tract infection of rhesus macaques exposed to SARS-CoV-2, according to researchers from the U.S. National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases.  Discuss
New tools rapidly detect anti-SARS-CoV-2 antibodies
New tools using surrogate viruses may be useful for rapid testing to determine whether antibodies effectively neutralize SARS-CoV-2. The viral vector-based platform approach was published in the Journal of Experimental Medicine on July 21.  Discuss
Shape-shifting may provide coronavirus with a survival advantage
Conformational changes of the SARS-CoV-2 spike protein -- the target of many vaccines and therapies -- may have features that help the virus hide from the host immune system and survive longer in the environment, according to a study published in Science on July 21.  Discuss
Replicating RNA COVID-19 vaccine shows robust responses in early testing
A replicating RNA vaccine delivered with a lipid-based nanoparticle emulsion has been shown to produce potent antibodies against SARS-CoV-2 in mice and primates with a single immunization, according to a study published in Science Translational Medicine on July 20.  Discuss
Red blood cells offer potential to deliver vaccines
Scientists have developed a biomimetic vaccine-delivery strategy based on an innate immune function of red blood cells that can deliver vaccine nanoparticles to the spleen, according to a research article published in the Proceedings of the National Academy of Sciences on July 14.  Discuss
The race is on to create a COVID-19 vaccine. But what next?
Fears of continuing waves of infection with the SARS-CoV-2 virus have helped trigger an accelerated effort among drug developers to bring a coronavirus vaccine to market. But even after a vaccine is developed and approved, there are a host of other challenges that must be solved to make sure it is administered widely enough to protect society at large.  Discuss
Moderna reports positive results in COVID-19 vaccine trial
Moderna is reporting positive results with a COVID-19 vaccine candidate it is developing. The candidate, messenger RNA (mRNA)-1273, was safe and triggered immune responses in healthy adults, according to new results published July 14 in the New England Journal of Medicine.  Discuss
Life science instrumentation market adapts to COVID-19
To reflect the new realities of the analytical instrumentation market during the COVID-19 pandemic and in the subsequent pandemic-driven recession, Strategic Directions International, a sister company of The Science Advisory Board, has released its revised edition of the Global Assessment Report.  Discuss
How has SARS-CoV-2 evolved from bat coronavirus?
Structural comparison between a bat coronavirus and SARS-CoV-2 reveals specific characteristics that make the new virus more pathogenic, according to a new article published in Nature Structural and Molecular Biology on July 9.  Discuss
Conferences
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter